Amphastar Pharmaceuticals (AMPH) to Release Earnings on Thursday

Key Points

• Amphastar Pharmaceuticals is expected to announce its Q2 2025 earnings on August 6th, with analysts predicting earnings of $0.71 per share and revenue of $173.42 million.
• The company's shares opened at $21.67, with a market cap of $1.02 billion and a PE ratio of 7.85.
• Analyst reports indicate a predominance of "hold" ratings, with a consensus price target of $32.33 and notable reductions in target prices from various firms.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) is expected to be releasing its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Amphastar Pharmaceuticals to post earnings of $0.71 per share and revenue of $173.42 million for the quarter.

Amphastar Pharmaceuticals Stock Up 1.2%

NASDAQ:AMPH traded up $0.26 during trading hours on Friday, reaching $21.21. The company's stock had a trading volume of 440,154 shares, compared to its average volume of 454,819. The company has a market cap of $999.84 million, a price-to-earnings ratio of 7.68 and a beta of 0.76. Amphastar Pharmaceuticals has a one year low of $20.39 and a one year high of $53.96. The business's 50-day moving average is $23.71 and its 200-day moving average is $26.76. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.95 and a quick ratio of 2.02.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Amphastar Pharmaceuticals by 2.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company's stock worth $652,000 after purchasing an additional 613 shares in the last quarter. AQR Capital Management LLC raised its position in Amphastar Pharmaceuticals by 82.0% in the first quarter. AQR Capital Management LLC now owns 53,638 shares of the company's stock worth $1,555,000 after purchasing an additional 24,167 shares in the last quarter. Finally, Intech Investment Management LLC raised its position in Amphastar Pharmaceuticals by 43.0% in the first quarter. Intech Investment Management LLC now owns 60,289 shares of the company's stock worth $1,748,000 after purchasing an additional 18,133 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AMPH. Wells Fargo & Company cut their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $32.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.